ENGOT OV50 / INNOVATE 3

Samenvatting

ENGOT-ov50/ INNOVATE-3 (EF-28)
Randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer.

Primair eindpunt

Overall survival (OS)

Aantal benodigde patiënten

540 (enrollment period 30 months)

Contactgegevens

Ingrid Boere

Deelnemende centra: AMC, Erasmus, MUMC, UMCU, Catharina